Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors

作     者：Chen Luohai Chen Jie Chen Luohai;Chen Jie

作者机构：Department of GastroenterologyThe First Affiliated HospitalSun Yat-sen UniversityGuangzhou 510080GuangdongChina 

出 版 物：《Journal of Pancreatology》 (胰腺病学杂志（英文）)

年 卷 期：2019年第2卷第3期

页      面：91-99页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：We thank the funding from Guangzhou Science and Technology Plan(201804010078) 

主　　题：Adjuvant therapy Neo-adjuvant therapy Pancreatic neuroendocrine tumors 

摘      要：The incidence rate of pancreatic neuroendocrine tumors(panNET)is increasing *** resection was the primary treatment choice for ***,till now,there were few studies concerning neo-adjuvant/conversion and adjuvant therapy for *** this article,we reviewed the currently widely used medical treatments for advanced *** seemed that peptide receptor radionuclide therapy(PRRT),chemotherapy(temozolomide-based or streptozocin-based)and sunitinib might be more effective to induce tumor shrinkage in panNET and therefore,these treatments could be tried in panNET when neo-adjuvant/conversion therapy was *** for adjuvant therapy,it was of great importance to identify patients with high risks of recurrence after curative surgery and previous studies found that high ki-67 index,large tumor size,lymphatic metastasis and perineural/vascular invasion,and so on,were correlated with early recurrence of *** PRRT and chemotherapy were more cytotoxic,these two kinds of therapies might be worth trying as adjuvant therapies in patients with high risks of recurrence after curative resection of ***,no studies discussed in this review directly investigated neo-adjuvant/conversion and adjuvant therapy for ***,more prospective studies were still warranted.